Skip to main content

Advertisement

Table 1 Characteristics of patients in the efficacy analysis group

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Characteristics of Patients n (%) or mean ± SD
Number 3316
Entry category  
   Type 1 diabetes, n/% 40 (1.2%)
   Type 2 diabetes, n/% 3235 (97.6%)
   Diabetes (diagnosis unknown), n/% 37 (1.1%)
   FBG ≥ 6.1 [mmol/l], n/% 4 (0.1%)
Outpatients, n/% 3212 (96.9%)
Men, n/% 2074 (62.5%)
Age, mean/SD 61.0 ± 12.0
≥65 yeas, n/% 1400 (42.2%)
BMI (kg/m2), mean/SD 25.7 ± 3.7
Smoking, n/% 825 (24.9%)
Alcohol consumption, n/% 1129 (34.0%)
Complication, n/% 2397 (72.3%)
   Hepatic disease, n/% 339 (10.2%)
   Kidney disease, n/% 51 (1.5%)
   Hypertension, n/% 1614 (48.7%)
Heart disease, n/% 325 (9.8%)
Duration of hyperlipidemia (years), mean/SD 4.7 ± 4.3
Duration of diabetes (years), mean/SD 6.6 ± 5.9
Previous treatment of hyperlipidemia, n/% 602 (18.2%)
Previous treatment of diabetes, n/% 1977 (59.6%)
Total cholesterol (mmol/l), mean/SD 5.76 ± 1.03
LDL cholesterol (mmol/l), mean/SD 3.19 ± 0.95
HDL cholesterol (mmol/l), mean/SD 1.18 ± 0.33
TG (mmol/l), mean/SD 3.72 ± 2.45
HbA1c (%), mean/SD 7.69 ± 1.52
FBG (mmol/l), mean/SD 9.01 ± 3.49
  1. aStandard Deviation